Browsing Tag
Autoimmune diseases
22 posts
How tetrahedral antibody design may improve efficacy and safety in immune-mediated diseases
Biomolecular Holdings LLC patents tetrahedral antibodies. Discover how this design could reshape efficacy and safety in immune-mediated diseases.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Antengene–UCB autoimmune deal: Why the $1.1bn ATG-201 partnership could reshape B-cell targeting therapies
Antengene licenses ATG-201 to UCB in a $1.1B autoimmune drug deal. Discover why bispecific antibodies are becoming the next frontier in immunology.
Is Orencia finally vulnerable? Dr. Reddy’s abatacept biosimilar clears a key FDA hurdle
Dr. Reddy’s abatacept biosimilar enters FDA review. See what this means for Orencia, biosimilar policy, and U.S. autoimmune drug pricing.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Simcere’s SIM0278 enters Phase II trial in China: Could IL-2 Treg fusion therapy transform atopic dermatitis care?
Simcere’s SIM0278 enters Phase II in China for atopic dermatitis. Explore how its IL-2 Treg selectivity could redefine treatment for autoimmune skin diseases.
Aurinia Pharmaceuticals posts positive Phase 1 data for aritinercept (AUR200) with implications for autoimmune disease treatment
Aurinia Pharmaceuticals reveals strong Phase 1 data for aritinercept (AUR200), signaling promise in autoimmune disease therapeutics. Read full clinical insights.
Aurinia Pharmaceuticals to present AUR200 Phase 1 trial data on June 30, 2025 in key webcast update
Aurinia Pharmaceuticals will release AUR200 Phase 1 results on June 30, 2025. Analysts await autoimmune insights. Join the webcast for full trial data.
Celltrion gains EC approval for Avtozma, a RoActemra biosimilar for autoimmune diseases
Celltrion has received marketing authorization from the European Commission (EC) for Avtozma, a biosimilar to RoActemra (tocilizumab), expanding…
Gloriosa Superba: Chemical constituents, medicinal uses, and pharmaceutical importance
Gloriosa superba, commonly referred to as the glory lily, is a highly valued medicinal plant recognized for its…